Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Vertex Pharmaceuticals Incorporated clinical trials
The registry lists 295 studies whose lead sponsor is Vertex Pharmaceuticals Incorporated or one of 6 companies grouped under it. 23 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the Vertex Pharmaceuticals Incorporated studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Vertex Pharmaceuticals Incorporated.
- Vertex Pharmaceuticals Incorporated249 studiesSame company
Something wrong?
- Crinetics Pharmaceuticals Inc.19 studies →Acquired — became part of Vertex Pharmaceuticals Incorporated, Sep 1, 2026 · source ↗
Something wrong?
- Nivalis Therapeutics, Inc.11 studies →Acquired — became part of Vertex Pharmaceuticals Incorporated, May 18, 2024 · source ↗
Something wrong?
- Alpine Immune Sciences, Inc.7 studies →Acquired — became part of Vertex Pharmaceuticals Incorporated, May 18, 2024 · source ↗
Something wrong?
- ViaCyte5 studies →Acquired — became part of Vertex Pharmaceuticals Incorporated, Sep 27, 2022 · source ↗
Something wrong?
- Alpine Immune Sciences Inc, A Subsidiary of Vertex3 studies →Acquired — became part of Vertex Pharmaceuticals Incorporated, May 18, 2024 · source ↗
Something wrong?
- Novocell1 study →Acquired — became part of Vertex Pharmaceuticals Incorporated, Sep 27, 2022 · source ↗
Something wrong?
Focus areas
Conditions Vertex Pharmaceuticals Incorporated leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 295. Browse all 295 →
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingNCT07890909Phase 3
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisRecruitingNCT07283770Phase 1
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyEnrolling by invitationNCT07807995Phase 3
- A Phase 1 Relative Bioavailability Study of a VX-581 Tablet FormulationRecruitingNCT07813039Phase 1
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)RecruitingNCT07159841Phase 2/3
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaRecruitingNCT07144163Phase 3
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT06628908Phase 3
- A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type IEnrolling by invitationNCT06926621Phase 2
- Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseNot yet recruitingNCT07868926Phase 1
- Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesRecruitingNCT07792408Phase 1
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsRecruitingNCT07437105Phase 1
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)RecruitingNCT07204275Phase 2/3
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisRecruitingNCT07501702Phase 2
- A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesRecruitingNCT04786262Phase 3
- Evaluation of Pain Treatment After Total Knee ArthroplastyRecruitingNCT07538570Phase 4
- A Long-term Follow-up Study in Participants Who Received CTX001Enrolling by invitationNCT04208529Phase 3
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT07231419Phase 3
- An Extension Study to Evaluate Safety and Efficacy of Atumelnant in Participants With Congenital Adrenal HyperplasiaRecruitingNCT06712823Phase 2
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Phase 1, First-in-human Study of VX-433RecruitingNCT07584434Phase 1
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyRecruitingNCT06619860Phase 2
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and OlderEnrolling by invitationNCT05844449Phase 3
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseaseRecruitingNCT05477563Phase 3
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantRecruitingNCT06832410Phase 3
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingNCT05732402Phase 1/2
Sponsor listed in the registry: Alpine Immune Sciences, Inc. · First submitted before Alpine Immune Sciences, Inc. became part of Vertex Pharmaceuticals Incorporated
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Active, not recruitingNCT06696443Phase 3
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedNCT05882357Phase 3
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine RegimenActive, not recruitingNCT07087054Phase 3
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney DiseaseActive, not recruitingNCT05312879Phase 2/3
- A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's SyndromeCompletedNCT05804669Phase 1/2
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid TumorsActive, not recruitingNCT07129252Phase 1/2
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyActive, not recruitingNCT05444257Phase 3
- A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesActive, not recruitingNCT05791201Phase 1/2
- A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)CompletedNCT05668741Phase 1/2
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingNCT05331183Phase 3
- Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Active, not recruitingNCT07161037Phase 2
- A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseCompletedNCT03745287Phase 2/3
- An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedNCT05757570Phase 1/2
Sponsor listed in the registry: Alpine Immune Sciences Inc, A Subsidiary of Vertex · First submitted before Alpine Immune Sciences Inc became part of Vertex Pharmaceuticals Incorporated
- Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)CompletedNCT05907291Phase 2
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06747572
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female ParticipantsCompletedNCT07378865Phase 1
- Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesCompletedNCT06794996Phase 2
- A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Active, not recruitingNCT06185764Phase 1/2
- Drug-Drug Interaction Study of Atumelnant in Healthy ParticipantsCompletedNCT07570082Phase 1
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy ParticipantsCompletedNCT07570069Phase 1
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisCompletedNCT06154447Phase 1
- A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)TerminatedNCT04261712Phase 2
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of AcromegalyTerminatedNCT04837040Phase 3
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)TerminatedNCT05192382Phase 3
Sponsor listed in the registry: Crinetics Pharmaceuticals Inc. · First submitted before Crinetics Pharmaceuticals Inc. became part of Vertex Pharmaceuticals Incorporated
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Active, not recruitingNCT05329649Phase 3
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Active, not recruitingNCT05356195Phase 3